{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:18:28Z","timestamp":1783372708136,"version":"3.54.6"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"national institute on aging","doi-asserted-by":"publisher","award":["R01AG017644"],"award-info":[{"award-number":["R01AG017644"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polypharmacy is common among older people and is associated with an increased mortality risk. However, little is known about whether the mortality risk is related to specific medications among older adults with polypharmacy. This study therefore aimed to investigate associations between high-risk medications and all-cause and cause-specific mortality among older adults with polypharmacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 1356 older adults with polypharmacy (5+ long-term medications a day for conditions or symptoms) from Wave 6 (2012\/2013) of the English Longitudinal Study of Ageing. First, using the agglomerative hierarchical clustering method, participants were grouped according to the use of 14 high-risk medication categories. Next, the relationship between the high-risk medication patterns and all-cause and cause-specific mortality (followed up to April 2018) was examined. All-cause mortality was assessed by Cox proportional hazards model and competing-risk regression was employed for cause-specific mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five high-risk medication patterns\u2014a renin-angiotensin-aldosterone system (RAAS) inhibitors cluster, a mental health drugs cluster, a central nervous system (CNS) drugs cluster, a RAAS inhibitors and antithrombotics cluster, and an antithrombotics cluster\u2014were identified. The mental health drugs cluster showed increased risks of all-cause (HR = 1.55, 95%CI = 1.05, 2.28) and cardiovascular disease (CVD) (SHR = 2.11, 95%CI = 1.10, 4.05) mortality compared with the CNS drug cluster over 6\u2009years, while others showed no differences in mortality. Among these patterns, the mental health drugs cluster showed the highest prevalence of antidepressants (64.1%), benzodiazepines (10.4%), antipsychotics (2.4%), antimanic agents (0.7%), opioids (33.2%), and muscle relaxants (21.5%). The findings suggested that older adults with polypharmacy who took mental health drugs (primarily antidepressants), opioids, and muscle relaxants were at higher risk of all-cause and CVD mortality, compared with those who did not take these types of medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study supports the inclusion of opioids in the current guidance on structured medication reviews, but it also suggests that older adults with polypharmacy who take psychotropic medications and muscle relaxants are prone to adverse outcomes and therefore may need more attention. The reinforcement of structured medication reviews would contribute to early intervention in medication use which may consequently reduce medication-related problems and bring clinical benefits to older adults with polypharmacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-021-02192-1","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:02:26Z","timestamp":1639620146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The impact of high-risk medications on mortality risk among older adults with polypharmacy: evidence from the English Longitudinal Study of Ageing"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-9198","authenticated-orcid":false,"given":"Yun-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Steptoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zaninotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"issue":"1","key":"2192_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. Available from. https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","journal-title":"BMC Geriatr"},{"key":"2192_CR2","volume-title":"Multimorbidity and polypharmacy 2019","author":"National Institute for Health and Care Excellence","year":"2019","unstructured":"National Institute for Health and Care Excellence. Multimorbidity and polypharmacy 2019 2019. Available from: https:\/\/www.nice.org.uk\/advice\/ktt18\/chapter\/Evidence-context."},{"key":"2192_CR3","volume-title":"Network contract direct enhanced service: draft outline service specifications","author":"NHS England and NHS Improvement","year":"2019","unstructured":"NHS England and NHS Improvement. Network contract direct enhanced service: draft outline service specifications. 2019. NHS England."},{"key":"2192_CR4","volume-title":"Polypharmacy and medicines optimisation: making it safe and sound","author":"M Duerden","year":"2013","unstructured":"Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation: making it safe and sound. London: King\u2019s Fund; 2013."},{"issue":"Suppl 2","key":"2192_CR5","doi-asserted-by":"publisher","first-page":"e180006","DOI":"10.1590\/1980-549720180006.supl.2","volume":"21","author":"NS Romano-Lieber","year":"2019","unstructured":"Romano-Lieber NS, Corona LP, Marques LFG, Secoli SR. Survival of the elderly and exposition to polypharmacy in the city of Sao Paulo, Brazil: SABE Study. Rev Bras Epidemiol. 2019;21(Suppl 2):e180006. Available from. https:\/\/doi.org\/10.1590\/1980-549720180006.supl.2.","journal-title":"Rev Bras Epidemiol"},{"issue":"1","key":"2192_CR6","doi-asserted-by":"publisher","first-page":"12615","DOI":"10.1038\/s41598-018-30840-9","volume":"8","author":"D Martinez-Gomez","year":"2018","unstructured":"Martinez-Gomez D, Guallar-Castillon P, Higueras-Fresnillo S, Banegas JR, Sadarangani KP, Rodriguez-Artalejo F. A healthy lifestyle attenuates the effect of polypharmacy on total and cardiovascular mortality: a national prospective cohort study. Sci Rep. 2018;8(1):12615. Available from. https:\/\/doi.org\/10.1038\/s41598-018-30840-9.","journal-title":"Sci Rep"},{"issue":"2","key":"2192_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ageing\/afs174","volume":"42","author":"SM Shah","year":"2013","unstructured":"Shah SM, Carey IM, Harris T, DeWilde S, Cook DG. Mortality in older care home residents in England and Wales. Age Ageing. 2013;42(2):209\u201315. Available from. https:\/\/doi.org\/10.1093\/ageing\/afs174.","journal-title":"Age Ageing"},{"issue":"5","key":"2192_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/jgs.12214","volume":"61","author":"CB Bowling","year":"2013","unstructured":"Bowling CB, Booth JN 3rd, Safford MM, Whitson HE, Ritchie CS, Wadley VG, et al. Nondisease-specific problems and all-cause mortality in the REasons for Geographic and Racial Differences in Stroke study. J Am Geriatr Soc. 2013;61(5):739\u201346. Available from. https:\/\/doi.org\/10.1111\/jgs.12214.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"2192_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/11592000-000000000-00000","volume":"28","author":"K Richardson","year":"2011","unstructured":"Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547\u201360. Available from. https:\/\/doi.org\/10.2165\/11592000-000000000-00000.","journal-title":"Drugs Aging"},{"issue":"4","key":"2192_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000365328","volume":"61","author":"C G\u00f3mez","year":"2015","unstructured":"G\u00f3mez C, Vega-Quiroga S, Bermejo-Pareja F, Medrano MJ, Louis ED, Benito-Le\u00f3n J. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2015;61(4):301\u20139. Available from. https:\/\/doi.org\/10.1159\/000365328.","journal-title":"Gerontology"},{"issue":"2","key":"2192_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/gerona\/61.2.170","volume":"61","author":"DV Espino","year":"2006","unstructured":"Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170\u20135. Available from. https:\/\/doi.org\/10.1093\/gerona\/61.2.170.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2192_CR12","doi-asserted-by":"publisher","unstructured":"Huang YT, Steptoe A, Wei L, Zaninotto P. Dose-response relationships between polypharmacy and all-cause and cause-specific mortality among older people. J Gerontol A Biol Sci Med Sci. 2021. Available from. https:\/\/doi.org\/10.1093\/gerona\/glab155.","DOI":"10.1093\/gerona\/glab155"},{"issue":"2","key":"2192_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1370\/afm.2501","volume":"18","author":"P Hanlon","year":"2020","unstructured":"Hanlon P, Quinn TJ, Gallacher KI, Myint PK, Jani BD, Nicholl BI, et al. Assessing risks of polypharmacy involving medications with anticholinergic properties. Ann Fam Med. 2020;18(2):148. Available from. https:\/\/doi.org\/10.1370\/afm.2501.","journal-title":"Ann Fam Med"},{"issue":"10","key":"2192_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/ggi.12907","volume":"17","author":"GB Sarbacker","year":"2017","unstructured":"Sarbacker GB, Espino DV, Wood RC, Oakes SL, Anand D, Markides KA. Total anticholinergic burden and survival within a cohort of elderly Mexican Americans. Geriatr Gerontol Int. 2017;17(10):1515\u201321. Available from. https:\/\/doi.org\/10.1111\/ggi.12907.","journal-title":"Geriatr Gerontol Int"},{"issue":"2","key":"2192_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"K Ruxton","year":"2015","unstructured":"Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209\u201320. Available from. https:\/\/doi.org\/10.1111\/bcp.12617.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2192_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MAJ.0000000000000552","volume":"350","author":"UE Makris","year":"2015","unstructured":"Makris UE, Pugh MJ, Alvarez CA, Berlowitz DR, Turner BJ, Aung K, et al. Exposure to high-risk medications is associated with worse outcomes in older veterans with chronic pain. Am J Med Sci. 2015;350(4):279\u201385. Available from. https:\/\/doi.org\/10.1097\/MAJ.0000000000000552.","journal-title":"Am J Med Sci"},{"issue":"6","key":"2192_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/00001648-200111000-00017","volume":"12","author":"RJ Glynn","year":"2001","unstructured":"Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12(6):682\u20139. Available from. https:\/\/doi.org\/10.1097\/00001648-200111000-00017.","journal-title":"Epidemiology"},{"issue":"4","key":"2192_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","volume":"80","author":"EA Davies","year":"2015","unstructured":"Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80(4):796\u2013807. Available from. https:\/\/doi.org\/10.1111\/bcp.12596.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"2192_CR19","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.14930","volume":"65","author":"LB Gerlach","year":"2017","unstructured":"Gerlach LB, Olfson M, Kales HC, Maust DT. Opioids and other central nervous system-active polypharmacy in older adults in the United States. J Am Geriatr Soc. 2017;65(9):2052\u20136. Available from. https:\/\/doi.org\/10.1111\/jgs.14930.","journal-title":"J Am Geriatr Soc"},{"issue":"8)","key":"2192_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/SMJ.0b013e31825fed90","volume":"105","author":"JM Wooten","year":"2012","unstructured":"Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012;105(8)):437\u201345. Available from. https:\/\/doi.org\/10.1097\/SMJ.0b013e31825fed90.","journal-title":"South Med J"},{"key":"2192_CR21","unstructured":"Medication Safety in Polypharmacy. Geneva: World Health Organization; 2019. (WHO\/UHC\/SDS\/2019.11). Licence: CC BY-NC-SA 3.0 IGO. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1235792\/retrieve."},{"key":"2192_CR22","volume-title":"Performing a structured medication review","author":"National Institute for Health and Care Excellence","year":"2020","unstructured":"National Institute for Health and Care Excellence. Performing a structured medication review 2020 [Available from: https:\/\/pathways.nice.org.uk\/pathways\/medicines-optimisation\/medication-review#content=view-node:nodes-performing-structured-medication-review."},{"key":"2192_CR23","volume-title":"Polypharmacy Guidance, Realistic Prescribing","author":"Scottish Government Polypharmacy Model of Care Group","year":"2018","unstructured":"Scottish Government Polypharmacy Model of Care Group. Polypharmacy Guidance, Realistic Prescribing. 3rd ed; 2018. Scottish Government","edition":"3"},{"key":"2192_CR24","series-title":"East Melbourne2019","volume-title":"RACGP aged care clinical guide (Silver Book)","author":"The Royal Australian College of General Practitioners","year":"2020","unstructured":"The Royal Australian College of General Practitioners. RACGP aged care clinical guide (Silver Book). East Melbourne2019, 2020. Available from: https:\/\/www.racgp.org.au\/silverbook."},{"key":"2192_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/cpp52s001","volume":"52","author":"FW Bergert","year":"2014","unstructured":"Bergert FW, Braun M, Ehrenthal K, Fe\u00dfler J, Gross J, H\u00fcttner U, et al. Recommendations for treating adult and geriatric patients on multimedication. Int J Clin Pharmacol Ther. 2014;52:1\u201364. Available from. https:\/\/doi.org\/10.5414\/cpp52s001.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"2192_CR26","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1532-5415.2012.04188.x","volume":"60","author":"American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity","year":"2012","unstructured":"American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc. 2012;60(10):E1\u2013E25. Available from. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04188.x.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2192_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394. Available from. https:\/\/doi.org\/10.1111\/jgs.15767.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2192_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","volume":"44","author":"D O'Mahony","year":"2015","unstructured":"O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213\u20138. Available from. https:\/\/doi.org\/10.1093\/ageing\/afu145.","journal-title":"Age Ageing"},{"issue":"10","key":"2192_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0895-4356(92)90144-c","volume":"45","author":"JT Hanlon","year":"1992","unstructured":"Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045\u201351. Available from. https:\/\/doi.org\/10.1016\/0895-4356(92)90144-c.","journal-title":"J Clin Epidemiol"},{"key":"2192_CR30","volume-title":"Deprescribing Guidelines and Algorithms Ottawa","author":"Canadian Deprescribing Network","year":"2019","unstructured":"Canadian Deprescribing Network. Deprescribing Guidelines and Algorithms Ottawa 2019 [Available from: https:\/\/deprescribing.org\/resources\/deprescribing-guidelines-algorithms\/."},{"key":"2192_CR31","series-title":"UK Data Service: SN: 5050","doi-asserted-by":"publisher","DOI":"10.5255\/UKDA-SN-5050-23","volume-title":"English longitudinal study of ageing: waves 0-9, 1998-2019 [data collection]","author":"J Banks","year":"2021","unstructured":"Banks J, Batty GD, JJF B, Coughlin K, Crawford R, Marmot M, et al. English longitudinal study of ageing: waves 0-9, 1998-2019 [data collection], UK Data Service: SN: 5050. 36th ed; 2021. Available from. https:\/\/doi.org\/10.5255\/UKDA-SN-5050-23.","edition":"36"},{"issue":"6","key":"2192_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/ije\/dys168","volume":"42","author":"A Steptoe","year":"2013","unstructured":"Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. 2013;42(6):1640\u20138. Available from. https:\/\/doi.org\/10.1093\/ije\/dys168.","journal-title":"Int J Epidemiol"},{"key":"2192_CR33","volume-title":"The dynamics of ageing: the 2012 English Longitudinal Study of Ageing (Wave 6), Technical Report","author":"S Bridges","year":"2015","unstructured":"Bridges S, Hussey D, Blake M. The dynamics of ageing: the 2012 English Longitudinal Study of Ageing (Wave 6), Technical Report. London: National Centre for Social Research; 2015."},{"key":"2192_CR34","volume-title":"English Longitudinal Study of Ageing (ELSA)","author":"Institute for Fiscal Studies","year":"2016","unstructured":"Institute for Fiscal Studies. English Longitudinal Study of Ageing (ELSA) 2016 [Available from: https:\/\/www.elsa-project.ac.uk\/data-and-documentation."},{"key":"2192_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/9780470977811","volume-title":"Cluster analysis","author":"BS Everitt","year":"2011","unstructured":"Everitt BS, Landau S, Leese M, Stahl D. Cluster analysis. 5th ed. Chichester: Wiley; 2011.","edition":"5"},{"key":"2192_CR36","unstructured":"Reed College. Cluster Analysis in Stata n.d. [Available from: https:\/\/www.reed.edu\/psychology\/stata\/analyses\/advanced\/cluster.html."},{"key":"2192_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-5218-7","volume-title":"Market research: the process, data, and methods using Stata","author":"E Mooi","year":"2018","unstructured":"Mooi E, Sarstedt M, Mooi-Reci I. Market research: the process, data, and methods using Stata. 1st ed. Singapore: Springer; 2018.","edition":"1"},{"issue":"2","key":"2192_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/ageing\/afx184","volume":"47","author":"RO Teh","year":"2018","unstructured":"Teh RO, Menzies OH, Connolly MJ, Doughty RN, Wilkinson TJ, Pillai A, et al. Patterns of multi-morbidity and prediction of hospitalisation and all-cause mortality in advanced age. Age Ageing. 2018;47(2):261\u20138. Available from. https:\/\/doi.org\/10.1093\/ageing\/afx184.","journal-title":"Age Ageing"},{"issue":"446","key":"2192_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509. Available from. https:\/\/doi.org\/10.1080\/01621459.1999.10474144.","journal-title":"J Am Stat Assoc"},{"issue":"15","key":"2192_CR40","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/sim.4780141510","volume":"14","author":"KR Hess","year":"1995","unstructured":"Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14(15):1707\u201323. Available from. https:\/\/doi.org\/10.1002\/sim.4780141510.","journal-title":"Stat Med"},{"issue":"3","key":"2192_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/atm.2016.08.62","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z. Survival analysis in the presence of competing risks. Ann Transl Med. 2017;5(3):47. Available from. https:\/\/doi.org\/10.21037\/atm.2016.08.62.","journal-title":"Ann Transl Med"},{"issue":"3","key":"2192_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pnp.429","volume":"20","author":"S Bleakley","year":"2016","unstructured":"Bleakley S. Antidepressant drug interactions: evidence and clinical significance. Prog Neurol Psychiatry. 2016;20(3):21\u20137. Available from. https:\/\/doi.org\/10.1002\/pnp.429.","journal-title":"Prog Neurol Psychiatry"},{"issue":"4","key":"2192_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/ageing\/afq055","volume":"39","author":"GE Caughey","year":"2010","unstructured":"Caughey GE, Roughead EE, Shakib S, McDermott RA, Vitry AI, Gilbert AL. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing. 2010;39(4):488\u201394. Available from. https:\/\/doi.org\/10.1093\/ageing\/afq055.","journal-title":"Age Ageing"},{"issue":"5","key":"2192_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.18553\/jmcp.2014.20.5.467","volume":"20","author":"JV Pergolizzi Jr","year":"2014","unstructured":"Pergolizzi JV Jr, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, et al. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Spec Pharm. 2014;20(5):467\u201376. Available from. https:\/\/doi.org\/10.18553\/jmcp.2014.20.5.467.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2192_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jpm.2019.0260","volume":"23","author":"S Schear","year":"2019","unstructured":"Schear S, Patel K, Deng LX, Miaskowski C, Maravilla I, Garrigues SK, et al. Multimorbidity and opioid prescribing in hospitalized older adults. J Palliat Med. 2019;23(4):475\u201382. Available from. https:\/\/doi.org\/10.1089\/jpm.2019.0260.","journal-title":"J Palliat Med"},{"issue":"9","key":"2192_CR46","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1200\/JOP.18.00781","volume":"15","author":"R Desai","year":"2019","unstructured":"Desai R, Camacho F, Tan X, LeBaron V, Blackhall L, Balkrishnan R. Mental health comorbidities and elevated risk of opioid use in elderly breast cancer survivors using adjuvant endocrine treatments. J Oncol Pract. 2019;15(9):e777\u2013e86. Available from. https:\/\/doi.org\/10.1200\/JOP.18.00781.","journal-title":"J Oncol Pract"},{"key":"2192_CR47","volume-title":"Managing adverse drug effects in pain: focus on muscle relaxants: practical pain management","author":"L Kral","year":"2012","unstructured":"Kral L, Ustic S. Managing adverse drug effects in pain: focus on muscle relaxants: practical pain management; 2012. Available from: https:\/\/www.practicalpainmanagement.com\/treatments\/pharmacological\/non-opioids\/managing-adverse-drug-effects-pain-focus-muscle-relaxants."},{"issue":"1","key":"2192_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","volume":"9","author":"WF Gellad","year":"2011","unstructured":"Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11\u201323. Available from. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.02.004.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"2192_CR49","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5114\/fmpcr.2017.70818","volume":"19","author":"P Vatcharavongvan","year":"2017","unstructured":"Vatcharavongvan P, Puttawanchai V. Polypharmacy, medication adherence and medication management at home in elderly patients with multiple non-communicable diseases in Thai primary care. Family Med Primary Care Rev. 2017;19(4):412\u20136. Available from. https:\/\/doi.org\/10.5114\/fmpcr.2017.70818.","journal-title":"Family Med Primary Care Rev"},{"issue":"6","key":"2192_CR50","doi-asserted-by":"publisher","first-page":"e13489","DOI":"10.1111\/ijcp.13489","volume":"74","author":"S Anoopkumar-Dukie","year":"2020","unstructured":"Anoopkumar-Dukie S, Mey A, Hall S, Bernaitis N, Davey AK, Plummer D. Non-prescription medicines may contribute to non-adherence to prescription medicines in people living with chronic health conditions. Int J Clin Pract. 2020;74(6):e13489. Available from. https:\/\/doi.org\/10.1111\/ijcp.13489.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"2192_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","volume":"113","author":"S Weinmann","year":"2009","unstructured":"Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113(1):1\u201311. Available from. https:\/\/doi.org\/10.1016\/j.schres.2009.05.018.","journal-title":"Schizophr Res"},{"issue":"11","key":"2192_CR52","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775\u201386. Available from. https:\/\/doi.org\/10.7326\/0003-4819-146-11-200706050-00006.","journal-title":"Ann Intern Med"},{"issue":"22","key":"2192_CR53","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1001\/jama.2016.7789","volume":"315","author":"WA Ray","year":"2016","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA. 2016;315(22):2415\u201323. Available from. https:\/\/doi.org\/10.1001\/jama.2016.7789.","journal-title":"JAMA"},{"issue":"8","key":"2192_CR54","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/ggi.13330","volume":"18","author":"D Sevilla-Sanchez","year":"2018","unstructured":"Sevilla-Sanchez D, Molist-Brunet N, Gonzalez-Bueno J, Sola-Bonada N, Espaulella-Panicot J, Codina-Jane C. Prevalence, risk factors and adverse outcomes of anticholinergic burden in patients with advanced chronic conditions at hospital admission. Geriatr Gerontol Int. 2018;18(8):1159\u201365. Available from. https:\/\/doi.org\/10.1111\/ggi.13330.","journal-title":"Geriatr Gerontol Int"},{"issue":"S1","key":"2192_CR55","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1111\/jgs.2013.61.issue-s1","volume":"61","author":"N Campbell","year":"2013","unstructured":"Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc. 2013;61(S1):S142\u2013S3. Available from. https:\/\/doi.org\/10.1111\/jgs.2013.61.issue-s1.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2192_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41512-018-0035-4","volume":"2","author":"BG Feakins","year":"2018","unstructured":"Feakins BG, McFadden EC, Farmer AJ, Stevens RJ. Standard and competing risk analysis of the effect of albuminuria on cardiovascular and cancer mortality in patients with type 2 diabetes mellitus. Diagn Progn Res. 2018;2(1):13. Available from. https:\/\/doi.org\/10.1186\/s41512-018-0035-4.","journal-title":"Diagn Progn Res"},{"issue":"3","key":"2192_CR57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/aje\/kwn135","volume":"168","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329\u201335. Available from. https:\/\/doi.org\/10.1093\/aje\/kwn135.","journal-title":"Am J Epidemiol"},{"key":"2192_CR58","volume-title":"Community Pharmacy Contractual Framework five-year deal: year 2 (2020 to 2021)","author":"Department of Health and Social Care","year":"2020","unstructured":"Department of Health and Social Care. Community Pharmacy Contractual Framework five-year deal: year 2 (2020 to 2021) 2020 [updated 23 February. Available from: https:\/\/www.gov.uk\/government\/publications\/community-pharmacy-contractual-framework-2019-to-2024\/year-2-detail."},{"key":"2192_CR59","volume-title":"Medicines use review (MUR)\/new medicine services (NMS) drug lists","author":"NHS Business Services Authority","year":"2019","unstructured":"NHS Business Services Authority. Medicines use review (MUR)\/new medicine services (NMS) drug lists 2019 [Available from: https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/dispensing-contractors-information\/medicines-0."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02192-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:06:53Z","timestamp":1639620413000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02192-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02192-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was awarded by the NHS Health Research Authority South Central \u2013 Berkshire Research Committee Ref: 21\/SC\/0030.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"321"}}